Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EW vs BAX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

EW Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

EW Overall Winner 6-Pillar Tally: EW 4 – 2 BAX Matrix Metrics: EW 7 – 3 BAX

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Baxter International Inc. (BAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas BAX carries 33.7/100 (SELL) at $25.57 (12.6x Forward P/E, 7.6% operating margin).

  • Composite vs. Pillar Nuance: While BAX currently prints a higher short-term Unified Composite Score (33.7/100 SELL vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 7.6% operating margin) and revenue trajectory (+10.5% vs. +5.0% YoY).
  • Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and BAX (33.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EW vs BAX
EW NYSE Head-to-Head Winner
Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$106.66
-0.46% 1D
Market Cap $60.8B
TTM Revenue $6.67B
Forward P/E 31.6x
Beta / 30D Vol 0.44β · 24% Vol
Unified Composite Score
31.5 / 100 SELL
Tech 50.0 Fund 29.0 Flow 51.0 Mom 44.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.7% over 20 days), RSI 79
RSI-14: 79.4 · SMA20: $97.03 · SMA50: $90.77
BAX NYSE
Baxter International Inc.
Surgical & Medical Instruments & Apparatus
$25.57
-0.95% 1D
Market Cap $13.3B
TTM Revenue $11.6B
Forward P/E 12.6x
Beta / 30D Vol 0.96β · 48% Vol
Unified Composite Score
33.7 / 100 SELL
Tech 20.0 Fund 39.0 Flow 72.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 53
RSI-14: 53.4 · SMA20: $25.32 · SMA50: $24.54

6-Pillar Scorecard Institutional Category Breakdown (EW 4 – 2 BAX)

Columns: Metric · EW · BAX
1. Valuation Multiples BAX
Forward P/E 31.6x 12.6x
Trailing P/E 61.5x 12.4x
PEG Ratio 2.33x N/M
EV / Revenue 8.8x 1.7x
2. Growth & Scale EW
Revenue Growth (YoY) +10.5% +5.0%
Earnings Growth (YoY) +6.7% +36.8%
TTM Revenue (USD) $6.67B $11.6B
Market Cap $60.8B $13.3B
3. Profitability & Quality EW
Gross Margin 78.0% 33.4%
Operating Margin 28.8% 7.6%
Net Profit Margin 15.3% -6.2%
Return on Equity (ROE) 9.3% -9.0%
4. Balance Sheet & Cash Flow EW
Cash Generation (TTM) $1.42B $1.13B
Cash Flow Margin 21.3% 9.8%
Net Cash / Leverage $2.41B Net Cash $6.83B Net Debt (1.35x D/E)
Dividend Yield None (0.00%) 0.15%
5. Options & Positioning BAX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 24.6% (34th %ile) 205.7% (23rd %ile)
Put/Call OI Skew N/A 0.21x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat EW
OpEx & R&D Intensity 49.2% of Rev ($3.28B) 25.8% of Rev ($3.00B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EW (7) vs BAX (3)
Institutional Metric EW BAX Criterion Row Edge
Market Capitalization
Scale
$60.8B $13.3B Larger Scale EW
Trailing P/E Ratio
Valuation
61.5x 12.4x Lower Multiple BAX
Forward P/E Ratio
Valuation
31.6x 12.6x Lower Multiple BAX
Revenue Growth (YoY)
Growth
+10.5% +5.0% Higher Growth EW
Operating Margin (TTM)
Profitability
28.8% 7.6% Higher Margin EW
Net Profit Margin
Profitability
15.3% -6.2% Higher Margin EW
Return on Equity (ROE)
Capital Efficiency
9.3% -9.0% Higher ROE EW
52-Week Range Position
Momentum
96% ($75–$108) 69% ($16–$30) Stronger Trend EW
Beta / 30D Volatility
Risk Regime
0.44β · 24% Vol 0.96β · 48% Vol Lower Realized Risk EW
Unified Institutional Score
Composite Signal
31.5 / 100 (SELL) 33.7 / 100 (SELL) Higher Composite BAX
Trailing 12M Revenue (USD)
Operating Scale
$6.67B $11.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
78.0% 33.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.33x PEG · 8.8x EV/Rev N/M PEG · 1.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.42B ($2.41B Net Cash) $1.13B ($6.83B Net Debt (1.35x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EW +22.03 pp
EW: +23.16% · BAX: +1.13%
3M Horizon EW +18.68 pp
EW: +17.23% · BAX: -1.45%
6M Horizon BAX +14.25 pp
EW: +29.45% · BAX: +43.7%
1Y Horizon BAX +12.85 pp
EW: +23.86% · BAX: +36.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EW Revenue BAX Revenue EW Op. Margin BAX Op. Margin Margin Leader
FY2018 $3.72B $11.1B 20.1% 14.3% EW
FY2019 $4.35B $11.4B 26.4% 15.6% EW
FY2020 $4.39B $11.7B 20.5% 13.8% EW
FY2021 $5.23B $12.2B 32.3% 11.1% EW
FY2022 $4.46B $10.1B 33.6% -28.3% EW
FY2023 $5.01B $10.4B 26.1% 6.8% EW
FY2024 $5.44B $10.6B 25.3% 0.1% EW
FY2025 $6.07B $11.2B 20.8% -2.7% EW

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EW UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 24.6%
IV Percentile 34th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact EW Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BAX CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 205.7%
IV Percentile 23rd %ile
Put/Call OI Skew 0.21x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact BAX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EW Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $60.8B market capitalization and 28.8% operating margin.
OpEx & R&D Reinvestment 49.2% of Rev ($3.28B)
90D Engineering Disclosures 0 Published
BAX Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $13.3B market capitalization and 7.6% operating margin.
OpEx & R&D Reinvestment 25.8% of Rev ($3.00B)
90D Engineering Disclosures 0 Published

Investor FAQ EW vs BAX Key Questions & Quantitative Answers

As of Nov 16, 2026, Edwards Lifesciences Corp (EW) is the stronger overall head-to-head candidate over Baxter International Inc. (BAX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). EW carries a Unified Composite Score of 31.5/100 (SELL) at $106.66 (31.6x Forward P/E, 28.8% operating margin), whereas BAX carries 33.7/100 (SELL) at $25.57 (12.6x Forward P/E, 7.6% operating margin). Composite vs. Pillar Nuance: While BAX currently prints a higher short-term Unified Composite Score (33.7/100 SELL vs. EW 31.5/100 SELL), EW captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (28.8% vs. 7.6% operating margin) and revenue trajectory (+10.5% vs. +5.0% YoY). Defensive Composite Rating Caution: Although EW compares more favorably head-to-head, both EW (31.5/100 SELL) and BAX (33.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

EW leads the Growth & Scale pillar: EW posts +10.5% YoY revenue growth and +6.7% YoY earnings growth on $6.67B TTM revenue (78.0% gross margin, 28.8% operating margin), compared with BAX at +5.0% YoY revenue growth and +36.8% YoY earnings growth on $11.6B TTM revenue (33.4% gross margin, 7.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), EW cumulative revenue shifted +63.2% while BAX shifted +1.3%. In operating R&D and SG&A reinvestment, EW deploys 49.2% of Rev ($3.28B) (0 90-day corporate R&D disclosures) versus 25.8% of Rev ($3.00B) (0 disclosures) for BAX.

BAX screens cheaper on headline valuation multiples. EW trades at 31.6x Forward P/E, 61.5x Trailing P/E, 2.33x PEG, and 8.8x EV/Revenue (21.3% FCF margin), whereas BAX trades at 12.6x Forward P/E, 12.4x Trailing P/E, N/M PEG, and 1.7x EV/Revenue (9.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EW (9.3% ROE) versus BAX (-9.0% ROE) capital efficiency.

In options market volatility and institutional positioning, EW carries 24.6% implied volatility (34th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 24% Vol realized risk). By comparison, BAX carries 205.7% implied volatility (23rd %ile, Compressed (<25th %ile)), a 0.21x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.